This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pot Stocks: Who Has the Best Earnings Chart?
by Tracey Ryniec
Pot stocks are entering the investing mainstream but do they have what it takes to compete against mature industries?
Can Canadian Market Drive Canopy Growth (CGC) Q3 Earnings?
by Zacks Equity Research
Canopy Growth (CGC) is expected to benefit from solid top-line contribution from the Canadian medical cannabis market and the legalization of the recreational use of cannabis in Q3.
Will Q4 Results Continue to Fuel Momentum in Marijuana ETF?
by Sweta Killa
Investors are keenly watching whether legalization is living up to the hype in the quarterly results of the cannabis stocks.
Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $46.93, marking a +0.86% move from the previous day.
Buy the Dip in Marijuana Stocks & ETF?
by Sanghamitra Saha
Marijuana stocks and ETF slumped on Feb 6. Is this the time to buy?
Marijuana ETF Joins Billion Dollar Club
by Sweta Killa
Marijuana ETF has now accumulated billion dollars in AUM since its inception in less than 14 months.
Pot Stocks are on a High: Play These Marijuana ETFs
by Sanghamitra Saha
As marijuana stocks soar into the new year, which ETFs should investors consider?
The Zacks Analyst Blog Highlights: Cronos, Altria, Canopy and Tilray
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cronos, Altria, Canopy and Tilray
Here's Why Cannabis Stocks (ACB, CRON) Are Gaining Today
by Ryan McQueeney
Shares of several notable cannabis stocks, including Aurora Cannabis (ACB) and Cronos Group (CRON), were up more than 10% through early afternoon trading hours Monday.
5 Top Performing Stocks of Marijuana ETF
by Sweta Killa
We have highlighted five best-performing stocks of the top ETF of January.
Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $48.03, marking a +1.91% move from the previous day.
What Makes Marijuana ETF the Best Performer in January?
by Sanghamitra Saha
These are the factors that led marijuana ETF to see a strong start to 2019.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $43.45, moving -0.48% from the previous trading session.
The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Innovative Industrial Properties, KushCo and Canopy Growth
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Innovative Industrial Properties, KushCo and Canopy Growth
4 Marijuana Stocks That Look Profitable in 2019
by Tirthankar Chakraborty
Global consumer marijuana spending is estimated to climb 38% to $16.9 billion this year, up from a projected $12.2 billion last year, $9.5 billion in 2017, and $6.9 billion in 2016.
Earnings from Netflix & Big Banks, & This Week in Cannabis Deals
by Ryan McQueeney
Ryan McQueeney and Maddy Johnson discuss earnings results from Netflix and the big U.S. banks. The hosts also remember the legacy of Jack Bogle and chat about several new cannabis industry deals.
Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $42.77, moving +1.59% from the previous trading session.
Zacks Investment Ideas feature highlights: Tilray, Canopy and Cronos
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Tilray, Canopy and Cronos
A Week of Cannabis Investing Deals & Earnings Reports from GS, BAC, UAL
by Ryan McQueeney
Ryan McQueeney covers the latest Brexit news and Snap's executive exodus. He also recaps earnings results from Goldman Sachs, Bank of America, and United Air Lines. Later, he discusses a busy week for deals in the cannabis industry.
Tilray Teams Up With Authentic Brands, Stock Down on Sell-Off
by Zacks Equity Research
Tilray (TLRY) signs a marketing agreement with Authentic Brands Group to sell consumer cannabis products.
Why Marijuana ETF is on a High in 2019
by Sweta Killa
After being beaten down in the final quarter of 2018, pot stocks staged a nice comeback this year on the renewed appeal for riskier assets.
Canopy Growth (CGC) in Focus: Stock Moves 11.1% Higher
by Zacks Equity Research
Canopy Growth (CGC) shares rose more than 11% in the last trading session, amid huge volumes.
Tilray's Tuesday Slide Due to IPO Lockup Expiration
by David Borun
Tilray's biggest shareholder resolves to stay long for the foreseeable future
Cannabis Investing News: Why CHC & ACB Stock Climbed Today
by Ryan McQueeney
Cannabis investors saw a pair of notable moves in popular stocks on Monday, with Canopy Growth (CGC) moving 11% and Aurora Cannabis (ACB) adding nearly 7% on the back of exciting deals for both companies.
Tilray Shares Rally as Investor Plans Not to Sell Shares
by Zacks Equity Research
Tilray (TLRY) gains after Privateer Holdings decides not to sell shares in the first half of 2019.